RhumbLine Advisers’s Protalix BioTherapeutics PLX Stock Holding History

RhumbLine Advisers’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$108K	Buy	46,224 +407	+0.9%	+$862	﹤0.01%	3504
2026 Q1	$99.4K	Buy	45,817 +1,448	+3%	+$3.59K	﹤0.01%	3410
2025 Q4	$79.9K	Sell	44,369 -20,825	-32%	-$42.6K	﹤0.01%	3543
2025 Q3	$145K	Sell	65,194 -4,602	-7%	-$7.5K	﹤0.01%	3378
2025 Q2	$103K	Buy	+69,796	New	+$143K	﹤0.01%	3514
2024 Q3	–	Sell	-17,666	Closed	-$20.7K	–	4300
2024 Q2	$20.7K	Sell	17,666 -58,789	-77%	-$69.4K	﹤0.01%	3868
2024 Q1	$96.3K	Buy	76,455 +2,769	+4%	+$4.13K	﹤0.01%	3458
2023 Q4	$131K	Sell	73,686 -21,717	-23%	-$33.8K	﹤0.01%	3359
2023 Q3	$158K	Buy	95,403 +6,830	+8%	+$12.3K	﹤0.01%	3277
2023 Q2	$177K	Buy	+88,573	New	+$211K	﹤0.01%	3300

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RhumbLine Advisers's PLX Position: Q2 2026 in Review

RhumbLine Advisers increased its Protalix BioTherapeutics (PLX) stake by 0.89% in Q2 2026, buying an estimated $862 and bringing the position to 46,224 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

RhumbLine Advisers first reported a position in PLX in Q2 2023 and has held it in 10 quarters since. The position peaked at $177K in Q2 2023. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

RhumbLine Advisers held 46,224 shares of Protalix BioTherapeutics worth $108K as of Q2 2026.
RhumbLine Advisers bought 407 Protalix BioTherapeutics shares in Q2 2026, an estimated $862.
Protalix BioTherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3504 holding.
RhumbLine Advisers first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 10 quarters since.
RhumbLine Advisers's Protalix BioTherapeutics position peaked at $177K in Q2 2023.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.